Paraxanthine — Safety, Research, Risks & Legal Status

Not medical advice. Paraxanthine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	1,7-dimethylxanthine; enfinity; CAS 611-59-6
Category	Nootropic
Chemical name	1,7-dimethylxanthine (CAS 611-59-6)
Origin	Primary hepatic metabolite of caffeine in humans (~84% conversion via CYP1A2)
Unique mechanism vs. caffeine	PDE9 (phosphodiesterase type 9 / cGMP) inhibition - not shared by caffeine
Acute LD50 (rat)	829 mg/kg, approximately 2.3x higher safety margin than caffeine (367 mg/kg)
Regulatory status	Self-affirmed GRAS dietary supplement ingredient; FDA reference daily intake 300 mg; not a controlled substance
Commercial brand	enfinity (TSI Group Ltd, exclusive global distributor as of 2023)
US legal status	Legal in the United States as a dietary supplement ingredient. TSI Group's enfinity (trademarked paraxanthine) holds self-affirmed GRAS (Generally Recognized as Safe) status and does not require a New Dietary Ingredient (NDI) notification, as it is acknowledged by the FDA as a caffeine metabolite naturally occurring in humans and foods. It is not an FDA-approved drug, not a scheduled or controlled substance, and is currently sold commercially in the US in functional foods, beverages, and pouches. The FDA reference daily intake for paraxanthine is 300 mg (vs. 400 mg for caffeine).

What is Paraxanthine?

Paraxanthine is a naturally occurring methylxanthine alkaloid and the primary hepatic metabolite of caffeine in humans - approximately 84% of ingested caffeine is converted to paraxanthine via the CYP1A2 enzyme. It functions as a central nervous system stimulant with a nootropic profile. Unlike caffeine, paraxanthine additionally inhibits phosphodiesterase type 9 (PDE9), a cGMP-specific enzyme, which caffeine does not meaningfully inhibit. It has been commercially developed and branded as enfinity by TSI Group Ltd and is in early-stage commercial adoption as of 2023-2024.

How it works

Paraxanthine exerts its primary effects through competitive antagonism at adenosine A1 and A2A receptors, with binding potency reported to be higher than that of caffeine at these sites. This mechanism is shared with caffeine and underlies wakefulness, alertness, and cognitive stimulation. Uniquely, paraxanthine also inhibits PDE9 (phosphodiesterase type 9), potentiating nitric oxide-cGMP neurotransmission - a mechanism absent with caffeine. The combined adenosine antagonism and PDE9 inhibition is proposed to explain paraxanthine's reportedly lower anxiogenic burden and potentially superior cognitive effects relative to caffeine, though head-to-head human mechanistic studies remain limited in number and sample size.

Background & history

Paraxanthine has been recognized as a caffeine metabolite in pharmacokinetic literature for decades. It gained renewed commercial interest when enfinity energy, LLC developed it as a standalone dietary ingredient and filed an extensive IP portfolio (23+ patents). TSI Group Ltd secured exclusive global distribution rights in 2023, accelerating commercial rollout. As of 2024-2026, the compound is being explored beyond cognitive supplements: Plopii biotech filed a USPTO utility patent in 2026 for a paraxanthine-based OTC analgesic formulation pairing it with aspirin or acetaminophen. Human clinical trial data began appearing in peer-reviewed literature from 2021 onward.

What the research says

Human evidence is limited but exists. Published double-blind, placebo-controlled crossover studies (small samples, n approximately 20-30 per trial) report that 100-200 mg acute doses improve reaction time, memory accuracy, and sustained attention versus placebo (Nutrients, 2021; PMC, 2022). A 2024 study reported superior post-exercise cognitive recovery with paraxanthine compared to caffeine in healthy adults, though the study design details and replication status should be reviewed in the primary source. Two registered clinical trials (NCT06117280; NCT06628596, completed August 2024) have evaluated dose-response effects on energy, focus, appetite, and cognition. Preclinical data in rats and mice show enhanced memory, neuroplasticity markers, muscle mass, strength, and endurance vs. caffeine, but animal-to-human translation requires caution. The overall clinical evidence base is early-stage: trials are few, samples are small, and independent replication is limited. GRAS self-affirmation and toxicological studies support an acceptable safety signal, but long-term human safety data beyond 90-day animal studies are not yet available in the public literature.

Reported effects

Wakefulness and alertness (adenosine receptor antagonism, similar mechanism to caffeine)
Improved reaction time and sustained attention in acute human trials at 100-200 mg
Reported improvements in working memory and memory accuracy (small crossover trials)
Lower blood pressure elevation compared to caffeine in available human data
Anxiolytic rather than anxiogenic profile at studied doses, in contrast to caffeine
Possible post-exercise cognitive recovery benefit (single 2024 study, limited replication)
Preclinical (animal): enhanced neuroplasticity markers, muscle mass, and endurance - human applicability unconfirmed

Dosing & administration (informational)

Published human trials have used acute doses of 50-200 mg. The FDA's reference daily intake for paraxanthine under GRAS self-affirmation is 300 mg. These figures are drawn from the available clinical and regulatory literature and are presented for informational reference only - they do not constitute a dosing protocol or recommendation. Individuals considering use should consult a qualified clinician, particularly those with cardiovascular conditions, anxiety disorders, sleep disorders, sensitivity to stimulants, or who are pregnant or breastfeeding.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Acute LD50 in rats: 829 mg/kg, approximately 2.3x higher safety margin than caffeine (367 mg/kg)
90-day NOAEL in animal studies: 185 mg/kg (vs. 150 mg/kg for caffeine)
No mutagenicity or genetic toxicity identified in 90-day animal toxicity studies
No serious adverse events reported in human trials at doses of 50-200 mg
Lower blood pressure and anxiety burden vs. caffeine in available human data
Long-term human safety data beyond available short-term trials does not yet exist in the public literature
Standard stimulant cautions apply: potential sleep disruption, overstimulation, or cardiovascular effects at high doses or in sensitive individuals including those with arrhythmias, hypertension, anxiety disorders, or pregnancy

Drug & supplement interactions

P
a
r
a
x
a
n
t
h
i
n
e
s
h
a
r
e
s
t
h
e
a
d
e
n
o
s
i
n
e
a
n
t
a
g
o
n
i
s
m
m
e
c
h
a
n
i
s
m
w
i
t
h
c
a
f
f
e
i
n
e
;
c
o
m
b
i
n
e
d
u
s
e
m
a
y
p
r
o
d
u
c
e
a
d
d
i
t
i
v
e
s
t
i
m
u
l
a
n
t
e
f
f
e
c
t
s
.
C
Y
P
1
A
2
i
n
h
i
b
i
t
o
r
s
(
e
.
g
.
,
f
l
u
v
o
x
a
m
i
n
e
,
c
i
p
r
o
f
l
o
x
a
c
i
n
)
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
a
l
t
e
r
m
e
t
a
b
o
l
i
s
m
o
f
c
o
-
a
d
m
i
n
i
s
t
e
r
e
d
c
a
f
f
e
i
n
e
a
n
d
d
o
w
n
s
t
r
e
a
m
p
a
r
a
x
a
n
t
h
i
n
e
l
e
v
e
l
s
,
t
h
o
u
g
h
d
i
r
e
c
t
p
a
r
a
x
a
n
t
h
i
n
e
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
i
n
h
u
m
a
n
s
a
r
e
n
o
t
a
v
a
i
l
a
b
l
e
i
n
t
h
e
r
e
v
i
e
w
e
d
l
i
t
e
r
a
t
u
r
e
.
S
t
a
n
d
a
r
d
m
e
t
h
y
l
x
a
n
t
h
i
n
e
p
r
e
c
a
u
t
i
o
n
s
a
p
p
l
y
w
i
t
h
M
A
O
I
s
,
s
y
m
p
a
t
h
o
m
i
m
e
t
i
c
s
,
a
n
d
m
e
d
i
c
a
t
i
o
n
s
s
e
n
s
i
t
i
v
e
t
o
b
l
o
o
d
p
r
e
s
s
u
r
e
o
r
h
e
a
r
t
r
a
t
e
c
h
a
n
g
e
s
.
T
h
e
p
r
o
p
o
s
e
d
a
n
a
l
g
e
s
i
c
f
o
r
m
u
l
a
t
i
o
n
(
p
a
r
a
x
a
n
t
h
i
n
e
+
a
s
p
i
r
i
n
/
a
c
e
t
a
m
i
n
o
p
h
e
n
)
i
s
i
n
p
a
t
e
n
t
s
t
a
g
e
o
n
l
y
;
s
a
f
e
t
y
d
a
t
a
f
o
r
t
h
a
t
c
o
m
b
i
n
a
t
i
o
n
s
p
e
c
i
f
i
c
a
l
l
y
i
s
n
o
t
y
e
t
i
n
t
h
e
p
u
b
l
i
c
d
o
m
a
i
n
.

Who should avoid it

Combined use with caffeine or other stimulants without accounting for additive CNS stimulation
Use in individuals with uncontrolled hypertension, arrhythmia, or cardiac conditions
Use during pregnancy or lactation (no safety data)
Use in individuals with anxiety disorders sensitive to stimulants, absent clinician guidance
High doses in individuals taking CYP1A2-inhibiting medications (interaction data absent)
Use as a substitute for evaluated medical treatment of cognitive impairment

How it is commonly combined

Paraxanthine is marketed as a standalone alternative to caffeine rather than a caffeine complement. Preclinical and early human data suggest it may not require co-administration with caffeine to produce stimulant effects. The proposed analgesic pairing with aspirin or acetaminophen (Plopii patent, 2026) is not yet backed by published clinical safety or efficacy data. No well-characterized human-validated stacking protocols exist in the peer-reviewed literature as of the available research base.

Legal & regulatory. Legal in the United States as a dietary supplement ingredient. TSI Group's enfinity (trademarked paraxanthine) holds self-affirmed GRAS (Generally Recognized as Safe) status and does not require a New Dietary Ingredient (NDI) notification, as it is acknowledged by the FDA as a caffeine metabolite naturally occurring in humans and foods. It is not an FDA-approved drug, not a scheduled or controlled substance, and is currently sold commercially in the US in functional foods, beverages, and pouches. The FDA reference daily intake for paraxanthine is 300 mg (vs. 400 mg for caffeine).

Quality & harm reduction

P
a
r
a
x
a
n
t
h
i
n
e
(
a
s
e
n
f
i
n
i
t
y
)
i
s
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
f
r
o
m
a
n
a
m
e
d
s
u
p
p
l
i
e
r
(
T
S
I
G
r
o
u
p
L
t
d
)
w
i
t
h
a
d
o
c
u
m
e
n
t
e
d
I
P
p
o
r
t
f
o
l
i
o
a
n
d
G
R
A
S
d
o
s
s
i
e
r
.
A
s
w
i
t
h
a
l
l
d
i
e
t
a
r
y
s
u
p
p
l
e
m
e
n
t
s
,
t
h
i
r
d
-
p
a
r
t
y
b
a
t
c
h
t
e
s
t
i
n
g
(
N
S
F
,
I
n
f
o
r
m
e
d
S
p
o
r
t
,
o
r
e
q
u
i
v
a
l
e
n
t
)
i
s
n
o
t
g
u
a
r
a
n
t
e
e
d
a
c
r
o
s
s
a
l
l
f
i
n
i
s
h
e
d
p
r
o
d
u
c
t
s
i
n
c
o
r
p
o
r
a
t
i
n
g
t
h
e
i
n
g
r
e
d
i
e
n
t
.
C
o
n
s
u
m
e
r
s
s
o
u
r
c
i
n
g
p
a
r
a
x
a
n
t
h
i
n
e
t
h
r
o
u
g
h
c
h
a
n
n
e
l
s
o
t
h
e
r
t
h
a
n
e
s
t
a
b
l
i
s
h
e
d
e
n
f
i
n
i
t
y
-
b
r
a
n
d
e
d
p
r
o
d
u
c
t
s
s
h
o
u
l
d
t
r
e
a
t
s
u
p
p
l
y
c
h
a
i
n
v
e
r
i
f
i
c
a
t
i
o
n
a
s
u
n
k
n
o
w
n
.
C
e
r
t
i
f
i
c
a
t
e
o
f
A
n
a
l
y
s
i
s
a
n
d
t
h
i
r
d
-
p
a
r
t
y
t
e
s
t
i
n
g
d
o
c
u
m
e
n
t
a
t
i
o
n
s
h
o
u
l
d
b
e
r
e
q
u
e
s
t
e
d
f
r
o
m
a
n
y
f
i
n
i
s
h
e
d
p
r
o
d
u
c
t
s
u
p
p
l
i
e
r
.

Safer, legal alternative we recommend

Liver Let Live. For liver and metabolic support, our Liver Support formula is a legal supplement option covering a similar goal.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is paraxanthine the same as caffeine?

No. Paraxanthine is a distinct molecule (1,7-dimethylxanthine) that is the primary metabolite caffeine is broken down into in the human liver. They share adenosine receptor antagonism but paraxanthine additionally inhibits PDE9, a mechanism caffeine does not meaningfully engage. The two compounds have different pharmacological profiles, with paraxanthine showing a reportedly lower anxiogenic and cardiovascular burden in available human data.

Is paraxanthine legal to purchase in the United States?

Yes. Paraxanthine marketed under the enfinity brand holds self-affirmed GRAS status and is sold as a dietary supplement ingredient. It is not a controlled substance and does not require an NDI notification. As with all supplements, it is not FDA-approved as a drug.

What does the human evidence actually show?

A small number of double-blind, placebo-controlled crossover trials (n approximately 20-30 per study) have reported improvements in reaction time, memory accuracy, and sustained attention at acute doses of 100-200 mg. A 2024 study reported superior post-exercise cognitive recovery versus caffeine. Two registered trials (NCT06628596, NCT06117280) have completed enrollment. The evidence base is early-stage: trials are few, samples are small, and independent replication beyond the enfinity-associated research pipeline is limited. Preclinical data in rodents is supportive but animal-to-human translation requires caution.

What dose should I take?

This reference does not provide dosing recommendations. Published trials used acute doses of 50-200 mg, and the FDA GRAS dossier references 300 mg as a daily intake figure. These are informational data points from the literature, not a protocol. Please consult a qualified clinician before use, particularly if you have any cardiovascular condition, anxiety disorder, sleep disorder, or are taking medications.

Is paraxanthine safer than caffeine?

Available preclinical toxicology data show a higher LD50 and NOAEL for paraxanthine versus caffeine, and published human trials report lower blood pressure elevation and a less anxiogenic profile at studied doses. However, long-term human safety data are not yet available in the public literature, and the human trial sample sizes are small. The current evidence is favorable but not definitive.

Can I stack paraxanthine with caffeine?

No well-characterized human-validated stacking protocol exists. Combined use with caffeine would be expected to produce additive adenosine antagonism and stimulant effects, which may exceed intended intensity in sensitive individuals. The compound is marketed as a standalone caffeine alternative, not a complement to it.

References & further reading

PubMed: paraxanthine cognitive function dose-response Nutrients 2021 (PMID 34766889)
PubMed: acute paraxanthine ingestion cognition 2022 (PMID 35215644)
PubMed: paraxanthine supplementation muscle mass 2022 (PMID 35633662)
ClinicalTrials.gov: NCT06628596 (acute effects paraxanthine energy focus cognition, Iovate Health Sciences, completed 2024)
ClinicalTrials.gov: NCT06117280 (dose-response paraxanthine energy focus)